Last-resort leukemia combo shows early promise in tiny trial
NCT ID NCT04926285
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a combination of two drugs, venetoclax and omacetaxine, in 6 adults with acute myeloid leukemia (AML) whose cancer had stopped responding to venetoclax-based treatments. The main goal was to find the safest dose of omacetaxine when given with venetoclax. Researchers also looked for signs that the cancer shrank or disappeared. Because the trial is very small and early, it cannot yet say whether this combination works well.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Venetoclax and omacetaxine
- What this could lead to
- If this works, it could offer a new treatment option for people with acute myeloid leukemia whose cancer has stopped responding to venetoclax.
- What could go wrong
- This is a very early, small study (only 6 people) to find the right dose and check safety. It is not yet designed to prove the combination works, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?